Insight

The first round of chemotherapy in high-risk neuroblastoma patients – St. Baldrick’s Foundation

Elizabeth Sokol/luriechildrens.org

Dec 27, 2024, 17:53

The first round of chemotherapy in high-risk neuroblastoma patients – St. Baldrick’s Foundation

St. Baldrick’s Foundation shared a post on LinkedIn about a recent paper by Elizabeth Sokol et al. published in EJC Paediatric Oncology:

“In high-risk neuroblastoma patients, their response to the first round of chemotherapy can provide doctors with valuable insights into their chances of recovery.

A recent study by the Children’s Oncology Group revealed that certain factors, such as the tumor’s origin and specific genetic changes, were associated with poorer outcomes in patients who didn’t respond well to treatment.

Conversely, patients who responded positively had fewer of these factors impacting their survival.”

“Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology Group”

Authors: Elizabeth Sokol, Brian LaBarre, Navin Pinto, Susan Kreissman, Meaghan Granger, Julie Park, Rochelle Bagatell, Arlene Naranjo, Steven DuBois.

The first round of chemotherapy in high-risk neuroblastoma patients - St. Baldrick's Foundation

More posts featuring St. Baldrick’s Foundation.

Arlene Naranjo Brian LaBarre cancer Elizabeth Sokol Julie Park Meaghan Granger Navin Pinto neuroblastoma OncoDaily Oncology Rochelle Bagatell St. Baldrick's Foundation Steven DuBois Susan Kreissman

Oncologist Near Me – Giuseppe Curigliano: A Prominent Specialist in Breast Cancer Clinical Trials and Research

FDA Approves T-DXd for HR+, HER2-Low/Ultralow Breast Cancer Treatment

Oncologist Near Me - Hagop Kantarjian: A Legend in Leukemia Research and Treatment

New Paper Alert: Botensilimab and Balstilimab in Relapsed/Refractory Metastatic Sarcomas

Best of ASCOGI25